إصدارات الهيئة

نشرات اليقظة الدوائية

أولاً: التوعية الدوائية: 

Content Issue date Issue

- DHPC for Dimethyl Fumarate

- Safety Communication for Emicizumab

- Local Case Report: Cyclizine

- EPVC News

01/2021

(132) Newsletter-Hundred Thirty-two
January 2021

- SSRI/SNRI risk of post-partum hemorrhage 

- Local Case Report: Sildenafil 

- EPVC News

02/2021

(133) Newsletter-Hundred Thirty-three
February 2021

- Erythromycin Cardiac Risk and Interaction with Rivaroxaban 

- Local Case Report: Furosemide 

- EPVC News

03/2021

(134) Newsletter-Hundred Thirty-four
March 2021

- Erythromycin: Update on Risk of Infantile Hypertrophic Pyloric Stenosis 

- Local Case Report: Ceftriaxone 

- EPVC News

04/2021

(135) Newsletter-Hundred Thirty-five
April 2021

- Bupropion: risk of serotonin syndrome 

- Local Case Report: Warfarin

05/2021

(136) Newsletter-Hundred Thirty-six
May 2021

- Polyethylene glycol (PEG) laxatives and starch-based thickeners: risk of aspiration 

- Local Case Report: Interaction between Warfarin and Naproxen 

- EPVC News

06/2021

(137) Newsletter-Hundred Thirty-seven
June 2021

- Obeticholic acid: Restriction of use 

- Local Case Report: Fluorouracil 

- EPVC News

07/2021

(138) Newsletter-Hundred Thirty-eight
July 2021

- Bendamustine: Risk of nonmelanoma skin cancer

- Levodopa DHPC 2

- Local Case Report: Lamivudine and Sulipride

08/2021 (139) Newsletter-Hundred Thirty-nine
August 2021

- Colchicine: High risk of fatality with Colchicine over-dose 

- Fingolimod: Updated advice about the risks of serious liver injury and herpes meningoencephalitis 

- EPVC News

09/2021 (140) Newsletter-Hundred Forty
September 2021

- COVID-19 Vaccine Astra-Zeneca: Warning for Guillain-Barre syndrome

- Topical corticosteroids: Information on the risk of topical steroid withdrawal reactions                                  

- EPVC News

10/2021

(141) Newsletter-Hundred Forty One October 2021

- DHPC: COVID-19  mRNA  Vaccine Comirnaty: Risk of Myocarditis and Pericarditis.

- Local Case  Report:  A  Case  of Drug Abuse Resulted in Acute Renal  Injury,  Cardiomegaly, Muscle Weakness,  Ulcers,  Sepsis  and  Finally  Death  Following  Paraffin Oil, Anabolic Steroids and Synthol Local Administration

11/2021

(142) Newsletter-Hundred Forty two November 2021

 

ثانياً: خطابات موجهة لمقدمى الخدمات الصحية

Content Issue date Issue
As the leaflets available in the packs of Leflunomide tablets are currently undergoing important safety updates, we would like to inform you of these important safety updates till their implementation in packs. 03/2021 Leflunomide Safety Updates
COVID-19 Vaccine AstraZeneca: benefits outweigh the risks despite possible link to very rare blood clots with low blood platelets. 04/2021

AstraZeneca Covid 19 Vaccine Risk Of TTS April 2021

Preliminary data from a completed clinical trial in rheumatoid arthritis patients (A3921133) suggest a higher risk of major adverse cardiovascular events (MACE) and malignancies (excluding non-melanoma skin cancer (NMSC)) with tofacitinib as compared to patients treated with a TNF-alpha inhibitor.

04/2021 Tofacitinib Updated safety information
COVID-19 Vaccine AstraZeneca: benefits outweigh the risks despite possible link to very rare blood clots with low blood platelets. 06/2021

Astrazeneca Covid 19 Vaccine Risk Of TTS update June 2021

Capillary leak syndrome (CLS)

Thrombosis with thrombocytopenia syndrome (TTS)

06/2021 J&J Covid 19 Vaccine
Risk Of Capillary Leak Syndrome And TTS
It was noted that the dosing information (specifically the timing of dosing with respect to food) in the product information for the levodopa-containing products was not optimal: it did not make clear that dosing without food is possible, and maybe preferable for some patients.  06/2021 Updating Dosing Information Levodopa
COVID-19 Vaccine AstraZeneca: contraindication in individuals with previous capillary leak syndrome 06/2021 COVID-19 Vaccine AstraZeneca contraindication
COVID-19 Vaccine Janssen: Risk for immune thrombocytopenia (ITP) and venous thromboembolism (VTE) 10/2021 COVID-19 Vaccine Janssen Risk for immune thrombocytopenia
COVID-19 Vaccine AstraZeneca: Risk of thrombocytopenia (including immune thrombocytopenia) with or without associated bleeding 10/2021 COVID-19 Vaccine AstraZeneca Risk of thrombocytopenia
COVID-19 mRNA Vaccine Comirnaty: risk of myocarditis and pericarditis 11/2021 COVID-19 mRNA Vaccine Comirnaty: risk of myocarditis and pericarditi
COVID-19 mRNA Vaccine Spikevax (previously Moderna): risk of myocarditis and pericarditis
11/2021 DHPC for Moderna concerning pericarditis

 

جميع الحقوق محفوظة © 2021